Effect of the concentration of Ca2+ in the suspending medium on the responses of human and rabbit platelets to aggregating agents.
Packham MA, Bryant NL, Guccione MA, Kinlough-Rathbone RL, Mustard JF
Purpose
Conclusion
Studies (1)
Purpose
The purpose of this study was to determine the effects of Ca concentration in platelet suspension medium, anticoagulant used for PRP, and type of agonist used on aggregation, formation of TXB2, and release of serotonin.
Summary of Findings
When D-Phenylalanyl-L-prolyl-L-arginine chloromethyl ketone (PPACK) was used as an anticoagulant, the secondary phase of adenosine diphosphate (ADP)-induced aggregation was inhibited, serotonin was not released, and TXB2 was not formed, however, citrated PRP or PRP anticoagulated with both PPACK and citrate exhibited primary and secondary ADP-induced aggregation, TXB2 formation, and release of serotonin. The addition of Ca to modified Tyrode-albumin solution had an inhibitory effect on ADP-induced aggregation, serotonin release, and TXB2 formation among resuspended platelets. Aspirin blocked the second phase of ADP-induced aggregation, TXB2 formation, and serotonin release for platelets resuspended with no added Ca and for PRP anticoagulated with citrate or citrate and PPACK. The addition of RGDS to the medium or not stirring after ADP addition each decreased serotonin release and TXB2 formation. The addition of RGDS also blocked aggregation. Thrombin-induced aggregation and serotonin release were maximal in resuspended platelets with 0-2 mM added Ca, while TXB2 formation was maximal in platelet suspensions with no added Ca. Aspirin and indomethacin treatment had no effects on thrombin-induced platelet aggregation when 0-2 mM of Ca was added to the medium but a strong inhibition when 5 mM of Ca was added to the medium, and these treatments also reduced serotonin release. The secondary phase of aggregation did not occur during platelet activating factor (PAF)-induced aggregation when PPACK was used as the sole anticoagulant, and aspirin treatment inhibited the secondary phase of aggregation among PRP anticoagulated with citrate or PPACK and citrate. Collagen-induced aggregation, serotonin release, and TXB2 formation were greatest when no Ca was added to the medium. Arachidonic acid-induced aggregation and serotonin release were inhibited when 5 mM of Ca was added to the platelet suspension medium, and TXB2 formation did not occur when this agonist was used.
Biospecimens
FluidBloodFluidPlasmaPreservation Types
None (Fresh)Diagnoses
Not specifiedPlatforms
Cell count/volumeHematology/ auto analyzerSmall moleculeRadioimmunoassayPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Biospecimen Acquisition Anticoagulant CitratePPACKBiospecimen Aliquots and Components Biospecimen components 0 mM added Ca0.5 mM added Ca1 mM added Ca2 mM added Ca5 mM added Ca50 uM RGDS added500 uM aspirinIndomethacinNo aspirinNo indomethacinBiospecimen Aliquots and Components Biospecimen mixing StirredUnstirredBiospecimen Aliquots and Components Blood and blood products Platelet-rich plasmaPlateletsHematology/ auto analyzer Specific Reaction solution ADPArachidonic acidCollagenPAFThrombin